[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.220.238. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
May 1962

Intraocular Penetration of Vancomycin

Author Affiliations

Philadelphia
From the Research Department of the Wills Eye Hospital.

Arch Ophthalmol. 1962;67(5):608-611. doi:10.1001/archopht.1962.00960020608015
Abstract

Introduction  Vancomycin is a bactericidal antibiotic obtained from strains of Streptomyces orientalis and discovered in 1956 at the Eli Lilly Research Laboratories.3 It is active against staphylococci, hemolytic streptococci, enterococci, pneumococci, corynebacteria, and clostridia. All clinically isolated staphylococci are sensitive to vancomycin's action, and it has been used against a wide variety of staphylococci infections with excellent results.6,7 Vancomycin is particularly useful in the treatment of infections due to staphylococci which are resistant to other antibiotics such as penicillin, tetracycline, and erythromycin, and it is considered by some authorities to be among the drugs of choice in treating severe staphylococcic infections which are resistant to the commonly used antibiotics.1,2 High blood levels are readily attained following intravenous administration, and staphylococci are generally sensitive to less than 5μg. of vancomycin per milliliter.Vancomycin is currently available only as an intravenous preparation—Vancocin, intravenous—a product of Eli Lilly Laboratories. When

First Page Preview View Large
First page PDF preview
First page PDF preview
×